A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma-Reference-Cited by-同舟云学术

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Published:2009-07 Issue:2 Volume:146 Page:171-179
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Forero-Torres Andres,Leonard John P.,Younes Anas,Rosenblatt Joseph D.,Brice Pauline,Bartlett Nancy L.,Bosly Andre,Pinter-Brown Lauren,Kennedy Dana,Sievers Eric L.,Gopal Ajay K.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2009.07740.x/fullpdf

Reference23 articles.

1. Management of Hodgkin lymphoma;Ansell;Mayo Clinic Proceedings,2006

2. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma;Ansell;Journal of Clinical Oncology,2007

3. Phase I study of SGN-30, a chimeric monoclonal antibody (mAb), in patients with refractory or recurrent CD30+ hematologic malignancies;Bartlett;Blood,2002

4. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies;Bartlett;Blood,2008

5. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma;Borchmann;Blood,2002

Cited by 218 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule;2024-08-03

2. CAR-T cell therapy for hematological malignancies: History, status and promise;Heliyon;2023-11

3. Protein Engineering, a Robust Tool to Engineer Novel Functions in Protein;Protein & Peptide Letters;2023-07

4. CD30 as a therapeutic target in adult haematological malignancies: Where are we now?;British Journal of Haematology;2023-05-11

5. Advances in the treatment of Hodgkin's lymphoma (Review);International Journal of Oncology;2023-04-04